Drug Design, Development and Therapy (Aug 2017)
Onychomadesis associated with chemotherapy: case report and mini literature review
Abstract
Ang Li,1,2,* Yanqiong Li,1,3,* Lingzhi Ge,4 Ping Li,1,3 Wenfei Li1 1Department of Dermatology, Qianfoshan Hospital, Shandong University, Jinan, People’s Republic of China; 2Department of Clinical Medicine, Queen Mary School, Medical School, Nanchang University, Nanchang, People’s Republic of China; 3Department of Clinical Medicine, Taishan Medical college, Tai’an, People’s Republic of China; 4Department of Dermatology, Affiliated First Hospital of Taishan Medical college, Tai’an, People’s Republic of China *These authors contributed equally to this work Abstract: The side effects of chemotherapy drugs have increased in recent years, and some side effects can lead to onychomadesis. A 72-year-old woman who was diagnosed with an invasive ductal carcinoma of the right breast underwent a modified radical mastectomy in April 2015, followed by chemotherapy with capecitabine and nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Subsequently, the patient experienced palmoplantar redness, pain, onycholysis, a transparent serous exudate, and onychomadesis. The chemotherapy was discontinued, and the patient was treated with oral vitamin B6, a polymyxin ointment, and a high-energy red light. The palmoplantar redness and pain were alleviated after 1 month. However, although her fingernails improved, dysesthesia symptoms remained, and all her toenails exhibited defects or deformities at a 24-month follow-up. The symptoms of this disorder should be recognized by dermatologists. Keywords: capecitabine and nab-paclitaxel, side effects, onychomadesis loss of nail
